What Happened?
Cambridge, MA-based Triplet-Therapeutics Appointed Amy Lurier as Vice President, Talent Acquisition
About the Company
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington`s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.
About the Person
Amy Lurier is Vice President, Talent Acquisition at Triplet Therapeutics. Previously, Amy held various senior HR leadership roles in the industry.
Info Source
News
Short Profile